Literature DB >> 25200497

UGT1A1 sequence variants associated with risk of adult hyperbilirubinemia: a quantitative analysis.

Zhiwei Chen1, Dazhi Su1, Luoyan Ai1, Xiaoke Jiang1, Changwei Wu1, Qingqing Xu1, Xiaohan Wang1, Zhuping Fan2.   

Abstract

BACKGROUNDS AND AIMS: UDP-glucuronosyltransferase 1 A1 (UGT1A1) is an enzyme that transforms small lipophilic molecules into water-soluble and excretable metabolites. UGT1A1 polymorphisms contribute to hyperbilirubinemia. This study quantitatively associated UGT1A1 variants in patients with hyperbilirubinemia and healthy subjects.
METHODS: A total of 104 individuals with hyperbilirubinemia and 105 healthy controls were enrolled for genotyping and DNA sequencing UGT1A1 sequence variants, including the Phenobarbital Response enhancer module (PBREM) region, the promoter region (TATA box), and the 5 exons for quantitative association with hyperbilirubinemia.
RESULTS: Eleven UGT1A1 variants were revealed in the case and control subjects, four of which were novel coding variants. A variant of PBREM (UGT1A1*60) was found in 47.6% of the patients, a TA repeat motif in the 5-primer promoter region [A(TA)7TAA,UGT1A1*28] was found in 27.9% of the patients, and p.G71R (UGT1A1*6) was in 33.2% of the patients. For the healthy controls, the frequency of UGT1A1*60, UGT1A1*28 and UGT1A1*6 was 26.7%, 9.0% and 15.7%, respectively. Homozygous UGT1A1*28 and homozygous UGT1A1*6 were significantly associated with the risk of adult hyperbilirubinemia, with an odds ratio (OR) of 17.79 (95% CIs, 2.11-133.61) and 14.93 (95% CIs, 1.83-121.88), respectively. Quantitative analysis showed that sense mutation (including UGT1A1*6) and UGT1A1*28/*28, but not UGT1A1*60/*60 or UGT1A1*1/*28, was associated with increased serum total bilirubin (TB) levels. High linkage disequilibrium occurred between UGT1A1*60 and UGT1A1*28 (D'=0.964, r(2)=0.345).
CONCLUSIONS: This study identified four novel UGT1A1 coding variants, some of which were associated with increased serum TB levels. A quantitative approach to evaluate adult hyperbilirubinemia provides a more vigorous framework for better understanding of adult hyperbilirubinemia genetics.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Case and control study; Gene mutation; Hyperbilirubinemia; Single nucleotide polymorphism; UDP-glucuronosyltransferase 1

Mesh:

Substances:

Year:  2014        PMID: 25200497     DOI: 10.1016/j.gene.2014.09.009

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  9 in total

1.  Clinical UGT1A1 Genetic Analysis in Pediatric Patients: Experience of a Reference Laboratory.

Authors:  Ann M Moyer; Jennifer M Skierka; Katrina E Kotzer; Michelle L Kluge; John L Black; Linnea M Baudhuin
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

Review 2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Authors:  R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas
Journal:  Clin Pharmacol Ther       Date:  2015-11-09       Impact factor: 6.875

3.  UGT1A1 genotypes and unconjugated hyperbilirubinemia phenotypes in post-neonatal Chinese children: A retrospective analysis and quantitative correlation.

Authors:  Kuerbanjiang Abuduxikuer; Ling-Juan Fang; Li-Ting Li; Jing-Yu Gong; Jian-She Wang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

4.  Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia.

Authors:  Jie Bai; Lei Luo; Shuang Liu; Chen Liang; Li Bai; Yu Chen; Sujun Zheng; Zhongping Duan
Journal:  Front Genet       Date:  2019-10-31       Impact factor: 4.599

5.  Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor.

Authors:  Qian Li; Tao Sun; Hua Zhang; Wei Liu; Yu Xiao; Hongqi Sun; Wencheng Yin; Yanhong Yao; Yangchun Gu; Yan'e Liu; Fumei Yi; Qiqi Wang; Jinyu Yu; Baoshan Cao; Li Liang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20

6.  Gilbert or Crigler-Najjar syndrome? Neonatal severe unconjugated hyperbilirubinemia with P364L UGT1A1 homozygosity.

Authors:  Laura Cozzi; Federica Nuti; Irene Degrassi; Daniela Civeriati; Giulia Paolella; Gabriella Nebbia
Journal:  Ital J Pediatr       Date:  2022-04-18       Impact factor: 3.288

7.  Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy.

Authors:  Hsiang-Lin Tsai; Yen-Cheng Chen; Tzu-Chieh Yin; Wei-Chih Su; Po-Jung Chen; Tsung-Kun Chang; Ching-Chun Li; Ching-Wen Huang; Jaw-Yuan Wang
Journal:  Oncol Res       Date:  2022-02-17       Impact factor: 4.938

8.  Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.

Authors:  Hironori Fujii; Yunami Yamada; Daichi Watanabe; Nobuhisa Matsuhashi; Takao Takahashi; Kazuhiro Yoshida; Akio Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  2018-10-30       Impact factor: 3.333

9.  Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.

Authors:  Shaojun Chen; Li Hua; Chengjun Feng; Qia Mo; Mengzhuan Wei; Yongqi Shen; Zhan Lin; Guisheng Li; Junyi Xu; Chengxian Guo; Haixin Huang
Journal:  BMC Gastroenterol       Date:  2020-04-07       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.